Table 3 Reasons for discontinuation of bDMARDs in non-adjusted data
N | < 65 yr | 65–74 yr | ≥75 yr | ||||||
|---|---|---|---|---|---|---|---|---|---|
TNFi | ABA | TCZ | TNFi | ABA | TCZ | TNFi | ABA | TCZ | |
456 | 123 | 116 | 229 | 114 | 59 | 121 | 115 | 29 | |
Remission | 77 (16.9) | 9 (7.3) | 4 (3.4) | 24 (10.5) | 4 (3.5) | 3 (5.1) | 12 (9.9) | 4 (3.5) | 1 (3.4) |
Effect insufficiency | 66 (14.5) | 27 (22.0) | 18 (15.5) | 53 (23.1) | 23 (20.2) | 5 (8.5) | 22 (18.2) | 22 (19.1) | 5 (17.2) |
Adverse events | 43 (9.4) | 6 (4.9) | 10 (8.6) | 29 (12.7) | 12 (10.5) | 8 (13.6) | 22 (18.2) | 5 (4.3) | 2 (6.9) |
Others | 44 (9.6) | 8 (6.5) | 2 (1.7) | 15 (6.6) | 3 (2.6) | 1 (1.7) | 4 (3.3) | 5 (4.3) | 1 (3.4) |